Research programme: hepatitis C virus NS5 protein inhibitors - Bristol-Myers Squibb
Alternative Names: BMS-929075Latest Information Update: 20 Jun 2016
Price :
$50 *
At a glance
- Originator Bristol-Myers Squibb
- Class Indoles
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 20 Jun 2016 No development reported - Preclinical for Hepatitis C in USA (PO)
- 20 Jun 2013 Bristol-Myers Squibb withdraws a phase I trial in Hepatitis C (treatment-naive) prior to enrolment (NCT01525212)
- 31 Jan 2012 Preclinical trials in Hepatitis C in USA (unspecified route)